. | Hazard Ratio (95% CI) . | P . |
---|---|---|
Extent of resection: GTR vs incomplete | 0.42 (0.21–0.85) | .015 |
Age at study entry: 18–54 vs 55+ y | 1.25 (0.65–2.41) | .508 |
MGMT promoter: methylated vs unmethylated | 0.58 (0.30–1.11) | .100 |
KPS at study entry: 90%–100% vs KPS 50%–80% | 0.82 (0.43–1.54) | .528 |
Steroids at study entry: no vs yes | 0.82 (0.42–1.62) | .566 |
. | Hazard Ratio (95% CI) . | P . |
---|---|---|
Extent of resection: GTR vs incomplete | 0.42 (0.21–0.85) | .015 |
Age at study entry: 18–54 vs 55+ y | 1.25 (0.65–2.41) | .508 |
MGMT promoter: methylated vs unmethylated | 0.58 (0.30–1.11) | .100 |
KPS at study entry: 90%–100% vs KPS 50%–80% | 0.82 (0.43–1.54) | .528 |
Steroids at study entry: no vs yes | 0.82 (0.42–1.62) | .566 |
Abbreviations: GTR, gross total resection; MGMT, O6-methylguanine DNA methyltransferase.
Patients with complete clinical and imaging data (n = 52).
. | Hazard Ratio (95% CI) . | P . |
---|---|---|
Extent of resection: GTR vs incomplete | 0.42 (0.21–0.85) | .015 |
Age at study entry: 18–54 vs 55+ y | 1.25 (0.65–2.41) | .508 |
MGMT promoter: methylated vs unmethylated | 0.58 (0.30–1.11) | .100 |
KPS at study entry: 90%–100% vs KPS 50%–80% | 0.82 (0.43–1.54) | .528 |
Steroids at study entry: no vs yes | 0.82 (0.42–1.62) | .566 |
. | Hazard Ratio (95% CI) . | P . |
---|---|---|
Extent of resection: GTR vs incomplete | 0.42 (0.21–0.85) | .015 |
Age at study entry: 18–54 vs 55+ y | 1.25 (0.65–2.41) | .508 |
MGMT promoter: methylated vs unmethylated | 0.58 (0.30–1.11) | .100 |
KPS at study entry: 90%–100% vs KPS 50%–80% | 0.82 (0.43–1.54) | .528 |
Steroids at study entry: no vs yes | 0.82 (0.42–1.62) | .566 |
Abbreviations: GTR, gross total resection; MGMT, O6-methylguanine DNA methyltransferase.
Patients with complete clinical and imaging data (n = 52).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.